Gavreto (pralsetinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

NSCLC accounts for 80% to 85% of all lung cancers. Credit: Douglas Olivares/Shutterstock.



  • Gavreto (pralsetinib)
  • Gavreto (pralsetinib)
  • Gavreto (pralsetinib)